Company press releases

Viser 51 - 100 av 141 resultater
Tid Selskap Tittel Sektor Kategori
08 Jun 2023
14:34 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
08 Jun 2023
12:22 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
07 Jun 2023
19:08 CEST 		ULTIMOVACS Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 May 2023
08:00 CEST 		ULTIMOVACS Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
03 May 2023
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Apr 2023
07:00 CEST 		ULTIMOVACS Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2023
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Share Option Program 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Apr 2023
15:08 CEST 		ULTIMOVACS Ultimovacs ASA - Annual General Meeting held on 20 April 2023 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
14 Apr 2023
08:00 CEST 		ULTIMOVACS Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting 20103010 Biotechnology Total number of voting rights and capital
13 Apr 2023
11:31 CEST 		ULTIMOVACS Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
24 Mar 2023
11:00 CET 		ULTIMOVACS Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
24 Mar 2023
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Annual Report 2022 20103010 Biotechnology Annual financial and audit Reports
27 Feb 2023
08:00 CET 		ULTIMOVACS Ultimovacs to Present at Cowen Healthcare Conference 20103010 Biotechnology Non-regulatory press releases
16 Feb 2023
08:00 CET 		ULTIMOVACS Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 Feb 2023
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
23 Jan 2023
08:00 CET 		ULTIMOVACS Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma - Additional regulated information required to be disclosed under the laws of a Member State
21 Dec 2022
10:27 CET 		ULTIMOVACS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Dec 2022
08:00 CET 		ULTIMOVACS Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial 20103010 Biotechnology Non-regulatory press releases
14 Dec 2022
08:00 CET 		ULTIMOVACS Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
29 Nov 2022
17:00 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
21 Nov 2022
07:00 CET 		ULTIMOVACS Ultimovacs ASA: New share capital registered 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
16 Nov 2022
11:56 CET 		ULTIMOVACS Ultimovacs ASA: Share capital increase related to exercise of options 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 Nov 2022
17:00 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
10 Nov 2022
08:00 CET 		ULTIMOVACS Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
03 Nov 2022
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Oct 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC) 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
18 Oct 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 Oct 2022
19:26 CEST 		ULTIMOVACS Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Sep 2022
16:30 CEST 		ULTIMOVACS Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR) 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
12 Sep 2022
15:05 CEST 		ULTIMOVACS Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 Sep 2022
08:53 CEST 		ULTIMOVACS Ultimovacs ASA: New share capital registered 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 Sep 2022
19:00 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
05 Sep 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA: Share capital increase related to exercise of options 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
22 Aug 2022
17:00 CEST 		ULTIMOVACS Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
19 Aug 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
18 Aug 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
12 Aug 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
30 Jun 2022
13:20 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
30 Jun 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Jun 2022
08:00 CEST 		ULTIMOVACS Ultimovacs' UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 May 2022
18:45 CEST 		ULTIMOVACS Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
12 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: First quarter 2022 result presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
22 Apr 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Share Option Program 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2022
11:14 CEST 		ULTIMOVACS Ultimovacs ASA - Annual General Meeting held on 21 April 2022 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Apr 2022
19:00 CEST 		ULTIMOVACS Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Apr 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting 20103010 Biotechnology Total number of voting rights and capital
30 Mar 2022
11:00 CEST 		ULTIMOVACS Ultimovacs to host Investor Days 2022: Meet the Team 20103010 Biotechnology Non-regulatory press releases